Armata Pharmaceuticals, INC. (ARMP) — 10-Q Filings

10-Q Filings (6)

• Armata's Net Loss Doubles to $49.5M, Raising Going Concern Doubts — Nov 12, 2025 Risk: high
  Armata Pharmaceuticals, Inc. (ARMP) reported a significant increase in net loss for the nine months ended September 30, 2025, reaching $49.5 million, compared t
• Armata's Q2 Loss Widens Amidst R&D Spend, Secures New Loan — Aug 12, 2025 Risk: high
  Armata Pharmaceuticals, Inc. reported no revenue for the three and six months ended June 30, 2025, consistent with the prior year periods, as it remains a clini
• Armata Pharmaceuticals Files Q1 2025 10-Q — May 14, 2025 Risk: medium
  Armata Pharmaceuticals, Inc. filed its 10-Q for the period ending March 31, 2025. The filing details financial performance and operational updates for the first
• Armata Pharmaceuticals Files Q3 2024 10-Q — Nov 13, 2024 Risk: medium
  Armata Pharmaceuticals, Inc. filed its 10-Q for the period ending September 30, 2024. The company, formerly AmpliPhi Biosciences Corp, is involved in biological
• Armata Pharmaceuticals Files Q2 2024 10-Q — Aug 13, 2024 Risk: medium
  Armata Pharmaceuticals, Inc. filed its 10-Q for the period ending June 30, 2024. The filing details financial performance and operational updates for the second
• Armata Pharmaceuticals, Inc. Files 10-Q for Period Ending March 31, 2024 — May 7, 2024 Risk: medium
  Armata Pharmaceuticals, Inc. (ARMP) filed a Quarterly Report (10-Q) with the SEC on May 7, 2024. Armata Pharmaceuticals, Inc. filed a 10-Q report for the period

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX